Period:
Draw Mode:
| Volume | 16,300 |
|
|||||
| News | - | ||||||
| Day High | 5.4616 | Low High |
|||||
| Day Low | 4.71 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Eloxx Pharmaceuticals Inc | ELOX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.18 | -3.59% | 4.84 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.98 | 4.71 | 5.4616 | 4.84 | 5.02 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 247 | 16,300 | $ 4.91 | $ 80,044 | - | 1.6959 - 10.90 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:17:41 | 3 | $ 4.60 | USD |
Eloxx Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 13.32M | 2.75M | - | 0 | -36.07M | -13.10 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Eloxx Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ELOX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.99 | 5.99 | 4.66 | 5.26 | 28,400 | -1.15 | -19.2% |
| 1 Month | 4.59 | 6.13 | 4.54 | 5.39 | 36,482 | 0.25 | 5.45% |
| 3 Months | 3.97 | 10.50 | 3.5596 | 7.78 | 1,074,045 | 0.87 | 21.91% |
| 6 Months | 2.84 | 10.90 | 2.2318 | 8.22 | 737,824 | 2.00 | 70.42% |
| 1 Year | 6.796 | 10.90 | 1.6959 | 7.55 | 445,483 | -1.96 | -28.78% |
| 3 Years | 102.00 | 270.80 | 1.6959 | 44.68 | 519,374 | -97.16 | -95.25% |
| 5 Years | 642.80 | 700.00 | 1.6959 | 69.20 | 355,167 | -637.96 | -99.25% |
Eloxx Pharmaceuticals Description
| Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel ribonucleic acid (RNA)-modulating drug candidates that are formulated to treat rare and ultra-rare premature stop codon diseases. The ELX-02, the company's lead investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins. The ELX-02, is in the early stages of clinical development for systemic administration for cystic fibrosis and cystinosis. |